Unknown

Dataset Information

Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma


ABSTRACT: Key Points • In a phase 3 clinical trial of FL, AICDA-mediated intraclonal heterogeneity was not prognostic.• TP53 mutated populations are common, subclonal, and their absence confers sensitivity to a radiation-containing regimen. Visual Abstract Abstract Although TP53 is commonly mutated in transformed follicular lymphoma, mutations are reported in <5% of pretreatment follicular lymphoma (FL) specimens. We assayed archival follicular B-cell non-Hodgkin lymphoma specimens from a completed clinical trial, Southwest Oncology Group S0016, a phase 3 randomized intergroup trial of CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone) chemotherapy plus R-CHOP (rituximab-CHOP) compared with CHOP chemotherapy plus 131-iodine tositumomab (radioimmunotherapy [RIT]-CHOP). Subclonal T

SUBMITTER: Burack W 

PROVIDER: S-EPMC10471938 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature